![](https://cdn.sanity.io/images/0vv8moc6/onclive/4b5e5a3ac846f4cf2a0b5334039796e2668391d6-200x200.png?fit=crop&auto=format)
De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer
Although adjuvant treatment regimens, such as ado-trastuzumab emtansine (T-DM1; Kadcyla) or trastuzumab (Herceptin) plus paclitaxel, have improved outcomes for patients with HER2-positive, early-stage breast cancer, developing more personalized treatment …